Skip to main content

Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme

Trial Status: Active

This study will collect blood and urine samples from patients undergoing radiation therapy for glioblastoma multiforme (a type of brain tumor) to investigate the effects of this treatment on blood cells and certain proteins. The information from this study may help scientists develop new tests to measure radiation exposure and find new ways to treat cancer with radiation, and help determine which kinds of patients or tumors respond better to radiation therapy. Two proteins of particular interest in this study and which may be involved in the recurrence of cancer are VEGF (vascular endothelial growth factor) and MMPs (matrix metalloproteinases). Patients 18 years of age and older with glioblastoma multiforme who are receiving or will receive radiation therapy as part of their medical treatment may be eligible for this study. Candidates are screened with a history and physical examination, blood tests, and magnetic resonance imaging (MRI) of the brain. Participants will have blood and urine samples collected before, during and after completion of their radiation treatment. Urine samples are collected in a cup and about 2 tablespoons of blood are withdrawn through a needle in a vein. Additional samples may be requested at different times during treatment and in the 3-year follow-up period.

Inclusion Criteria

  • - INCLUSION CRITERIA: Age greater than or equal to 18 years Histologically confirmed supratentorial Glioblastoma multiforme Karnofsky performance greater than 60 Patient must be a candidate for radiotherapy Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: Patients with other cancers excluding nonmelanomatous skin cancers or carcinoma in situ Gliadel wafer placement at the time of surgery Pregnant women are excluded from this study because radiation has the potential for teratogenic or abortifacient effects. <TAB><TAB>

Maryland

Bethesda
National Institutes of Health Clinical Center
Status: ACTIVE
Contact: National Cancer Institute Referral Office
Phone: 888-624-1937

BACKGROUND

- Preliminary data generated from our pilot protocol 02-C-0064 suggests that the urinary

VEGF and MMP level at the one month follow-up time point compared to the last

on-treatment time point collection may be predictive of tumor recurrence at one year

(l).

- Note that this preliminary study included patients with all histologies.

- In an on ongoing effort to validate our results with a larger more homogeneous patient

cohort we propose to prospectively study patients undergoing radiotherapy for GBM.

OBJECTIVES

-We will determine whether VEGF and MMP level measurements aide in predicting tumor

recurrence at 1 year.

ELIGIBILITY

-Patients seen in the radiation oncology clinic will be asked to provide samples of blood and

urine before, during and after their radiation treatment.

DESIGN

- This protocol-provides a means of acquiring blood and urine samples from patients

receiving radiation therapy for Glioblastoma multiforme (GBM).

- Patients will be analyzed according to their Radiation Therapy Oncology Group (RTOG)

recursive partitioning prognostic subgroups, which includes patient age, KPS, extent of

resection and neurological function.

Trial Phase Phase NA

Trial Type Not provided by clinicaltrials.gov

Lead Organization
National Cancer Institute

Principal Investigator
Kevin Camphausen

  • Primary ID 040200
  • Secondary IDs NCI-2018-02352, 04-C-0200, NCI-2015-01215
  • Clinicaltrials.gov ID NCT00083512